Oxcarbazepine (Epilepsy)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7659
R22651		 Tomson (Oxcarbazepine) , 2018 Hypospadias at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 0.58 [0.03;10.32] C 0/333   6/2,514 6 333
ref
S6071
R15802		 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.58 [0.39;149.00] C 0/7   6/647 6 7
ref
Total 2 studies 2.04 [0.16;25.25] 12 340
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Oxcarbazepine) , 2018Tomson, 2018 1 0.58[0.03; 10.32]633351%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 7.58[0.39; 149.00]6749%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 32% 2.04[0.16; 25.25]123400.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine; 2: Oxcarbazepine) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.04[0.16; 25.25]1234032%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 2.04[0.16; 25.25]1234032%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 2.04[0.16; 25.25]1234032%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 2.04[0.16; 25.25]1234032%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.220.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.04[0.16; 25.25]1234032%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0